DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion

Cervical cancer (CC) patients with lymph node metastasis (LNM) have a poor prognosis. However, the molecular mechanism of LNM in CC is unclear, and there is no effective clinical treatment. Here, we found that 7-dehydrocholesterol reductase (DHCR7), an enzyme that catalyzes the last step of choleste...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2024-03, Vol.584, p.216609-216609, Article 216609
Main Authors: Mei, Xinyu, Xiong, Jinfeng, Liu, Jian, Huang, Anni, Zhu, Da, Huang, Yafei, Wang, Hui
Format: Article
Language:English
Subjects:
Cervical cancer
Cholesterol - metabolism
Female
Humans
Lymphangiogenesis
Lymphatic Metastasis
Oxidoreductases
Phosphatidylinositol 3-Kinases
Proto-Oncogene Proteins c-akt - metabolism
Tamoxifen
Tumor metabolism
Uterine Cervical Neoplasms - pathology
Vascular Endothelial Growth Factor C - genetics
Vascular Endothelial Growth Factor C - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cervical cancer (CC) patients with lymph node metastasis (LNM) have a poor prognosis. However, the molecular mechanism of LNM in CC is unclear, and there is no effective clinical treatment. Here, we found that 7-dehydrocholesterol reductase (DHCR7), an enzyme that catalyzes the last step of cholesterol synthesis, was upregulated in CC and closely related to LNM. Gain-of-function and loss-of-function experiments proved that DHCR7 promoted the invasion ability of CC cells and lymphangiogenesis in vitro and induced LNM in vivo. The LNM-promoting effect of DHCR7 was partly mediated by upregulating KN motif and ankyrin repeat domains 4 (KANK4) expression and subsequently activating the PI3K/AKT signaling pathway. Alternatively, DHCR7 promoted the secretion of vascular endothelial growth factor-C (VEGF-C), and thereby lymphangiogenesis. Interestingly, cholesterol reprogramming was needed for the DHCR7-mediated promotion of activation of the KANK4/PI3K/AKT axis, VEGF-C secretion, and subsequent LNM. Importantly, treatment with the DHCR7 inhibitors AY9944 and tamoxifen (TAM) significantly inhibited LNM of CC, suggesting the clinical application potential of DHCR7 inhibitors in CC. Collectively, our results uncover a novel molecular mechanism of LNM in CC and identify DHCR7 as a new potential therapeutic target. •DHCR7-mediated cholesterol metabolism reprogramming promotes lymph node metastasis.•KANK4 expression is regulated by DHCR7 and activates the PI3K/AKT pathway.•The secretion of VEGF-C controlled by DHCR7 promotes lymphangiogenesis.•Targeting DHCR7 prevents lymph node metastasis in cervical cancer.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2024.216609